Embryonic signaling in melanoma: Potential for diagnosis and therapy

41Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

As the frequency of melanoma diagnosis increases, current treatment strategies are still struggling to significantly impact patient survival. Some promise has been shown in treating certain melanomas by targeting activated signaling pathways resulting from specific mutations in proteins, such as BRAF and NRAS. Recently, the identification of embryonic signaling pathways in melanoma has helped us better understand certain biological characteristics, such as cellular heterogeneity and phenotypic plasticity, and has provided novel insight pertinent to diagnosis and therapy. For instance, our studies have shown that the TGF-Β family member, Nodal, is expressed in melanoma and is responsible, at least in part, for tumor cell plasticity and aggressiveness. Since the majority of normal adult tissues do not express Nodal, we reason that this embryonic morphogen could be used to identify and target aggressive melanoma cells. We have also identified that molecular cross-talk between the Notch and Nodal pathways may represent a mechanism responsible for the overexpression of Nodal in melanoma. Further exploitation of the relationship between embryonic signaling pathways and cancer pathogenesis could lead to novel approaches for diagnosis and therapy in cancers, such as melanoma. © 2011 USCAP, Inc All rights reserved.

Cite

CITATION STYLE

APA

Strizzi, L., Hardy, K. M., Kirsammer, G. T., Gerami, P., & Hendrix, M. J. C. (2011). Embryonic signaling in melanoma: Potential for diagnosis and therapy. Laboratory Investigation, 91(6), 819–824. https://doi.org/10.1038/labinvest.2011.63

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free